Sanjay Keswani Biography and Net Worth
Dr. Keswani joined Annexon Biosciences as Chief Medical Officer in June 2019. He is an accomplished physician-scientist with broad R&D expertise in multiple therapeutic areas and is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Dr. Keswani has held senior executive positions in the pharmaceutical industry, including Roche, where he was Senior Vice President and Global Head of Neuroscience, Ophthalmology and Rare diseases Research and Early Development. During his tenure at Roche, his group successfully advanced five molecules to Phase 3 development. Prior to Roche, he was Vice President, Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He also held R&D leadership roles at Eli Lilly & Co. and Amgen, Inc. where he prosecuted the development of the now - approved CGRP antibodies for migraine prevention, Emgality and Aimovig.
Dr. Keswani completed his residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins, where he cared for patients with diverse neurological diseases and ran a R01-funded Neuroimmunology research lab. He graduated in medicine at St. Bartholomew’s Hospital (England’s oldest medical school founded in 1123). In addition, he holds a First Class honors BSc degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences (Immunology).
What is Sanjay Keswani's net worth?
The estimated net worth of Sanjay Keswani is at least $12,464.40 as of March 24th, 2021. Dr. Keswani owns 3,995 shares of Annexon stock worth more than $12,464 as of June 7th. This net worth approximation does not reflect any other investments that Dr. Keswani may own. Learn More about Sanjay Keswani's net worth.
How do I contact Sanjay Keswani?
Has Sanjay Keswani been buying or selling shares of Annexon?
Sanjay Keswani has not been actively trading shares of Annexon during the last quarter. Most recently, Sanjay Keswani sold 3,995 shares of the business's stock in a transaction on Wednesday, March 24th. The shares were sold at an average price of $30.17, for a transaction totalling $120,529.15. Following the completion of the sale, the executive vice president now directly owns 3,995 shares of the company's stock, valued at $120,529.15. Learn More on Sanjay Keswani's trading history.
Who are Annexon's active insiders?
Are insiders buying or selling shares of Annexon?
During the last twelve months, Annexon insiders bought shares 2 times. They purchased a total of 2,753,988 shares worth more than $10,062,313.92. During the last twelve months, insiders at the sold shares 2 times. They sold a total of 3,243 shares worth more than $20,448.32. The most recent insider tranaction occured on May, 25th when Major Shareholder Bain Capital Life Sciences Inv bought 300,000 shares worth more than $639,000.00. Insiders at Annexon own 19.1% of the company.
Learn More about insider trades at Annexon. Information on this page was last updated on 5/25/2023.
Sanjay Keswani Insider Trading History at Annexon
| Transaction Date | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/24/2021 | Sell | 3,995 | $30.17 | $120,529.15 | 3,995 |  |
Annexon Company Overview
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Read More
Volume
1,617,754 shs
Average Volume
685,122 shs
Market Capitalization
$165.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.5
